Characterization of Patients with Arthritis Referred for Gold Therapy in the Era of Biologics

REFERENCES

1. 1.↵
   1. Eisler R

   . Chrysotherapy: A synoptic review. Inflamm Res 2003;52:487–501.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Case JP

   . Old and new drugs used in rheumatoid arthritis: A historical perspective. Part 1: The older drugs. Am J Ther 2001;8:123–43.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Noriega JLR,
   2. Harth M

   . Pharmacology of gold compounds in rheumatoid arthritis: A review. Can J Clin Pharmacol 1997;4:127–36.

   OpenUrl
4. 4.↵
   1. Lehman AJ,
   2. Esdaile JM,
   3. Klinkhoff AV,
   4. Grant E,
   5. Fitzgerald A,
   6. Canvin J

   . A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: Results of the METGO study. Arthritis Rheum 2005;52:1360–70.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Harris ED,
   2. Budd MD,
   3. Genovese MC,
   4. Firestein GS,
   5. Sergent JS,
   6. Ruddy S,
   7. Sledge CB

   1. Gordon DA,
   2. Klinkhoff AV

   . Second line agents. In: Harris ED, Budd MD, Genovese MC, Firestein GS, Sergent JS, Ruddy S, Sledge CB, editors. Kelley’s textbook of rheumatology. 7th ed. Chapter 58. Philadelphia: Elsevier Saunders; 2005:886–93.
6. 6.↵
   1. Nieminen R,
   2. Korhonen R,
   3. Moilanen T,
   4. Clark A,
   5. Moilanen E

   . Aurothiomalate inhibits cyclooxygenase 2, matrix metalloproteinase 3, and interleukin-6 expression in chondrocytes by increasing MAPK phosphatase 1 expression and decreasing p38 phosphorylation. Arthritis Rheum 2010;62:1650–9.

   OpenUrlPubMed
7. 7.↵
   1. Combe B,
   2. Landewe R,
   3. Lukas C,
   4. Bolosiu HD,
   5. Breedveld F,
   6. Dougados M,
   7. et al.

   EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34–45.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Saag KG,
   2. Teng GG,
   3. Patkar NM,
   4. Anuntiyo J,
   5. Finney C,
   6. Curtis JR,
   7. et al.

   American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762–84.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Smolen JS,
   2. Landewe R,
   3. Breedveld FC,
   4. Dougados M,
   5. Emery P,
   6. Gaujoux-Viala C,
   7. et al.

   EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964–75.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Pope JE,
    2. Hong P,
    3. Koehler BE

    . Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: A survey of practicing Canadian rheumatologists. J Rheumatol 2002;29:255–60.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Maetzel A,
    2. Bombardier C,
    3. Strand V,
    4. Tugwell P,
    5. Wells G

    . How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: A survey. J Rheumatol 1998;25:2331–8.

    OpenUrlPubMed
12. 12.↵
    1. Almarzouqi M,
    2. Scarsbrook D,
    3. Klinkhoff A

    . Gold therapy in women planning pregnancy: Outcomes in one center. J Rheumatol 2007;34:1827–31.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Wooley PH,
    2. Griffin J,
    3. Panayi GS,
    4. Batchelor JR,
    5. Welsh KI,
    6. Gibston TJ

    . HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med 1980;303:300–2.

    OpenUrlPubMed